These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20693174)

  • 1. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Rose WE; Knier RM; Hutson PR
    J Antimicrob Chemother; 2010 Oct; 65(10):2149-54. PubMed ID: 20693174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore.
    Sng LH; Koh TH; Wang GC; Hsu LY; Kapi M; Hiramatsu K
    Int J Antimicrob Agents; 2005 Feb; 25(2):177-9. PubMed ID: 15664490
    [No Abstract]   [Full Text] [Related]  

  • 7. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing Trend of Heterogeneous Vancomycin Intermediate Staphylococcus aureus in a Tertiary Care Center of Northern India.
    Singh A; Prasad KN; Misra R; Rahman M; Singh SK; Rai RP; Tripathi A; Srivastava JK
    Microb Drug Resist; 2015 Oct; 21(5):545-50. PubMed ID: 26430942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hVISA/VISA: diagnostic and therapeutic problems.
    Szabó J
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):1-3. PubMed ID: 19622051
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model.
    Rose WE; Leonard SN; Rossi KL; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2009 Feb; 53(2):805-7. PubMed ID: 19015334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Screening for Staphylococcus aureus with a reduced susceptibility to vancomycin in: a Belgian hospital].
    Piérard D; Vandenbussche H; Verschraegen I; Lauwers S
    Pathol Biol (Paris); 2004 Oct; 52(8):486-8. PubMed ID: 15465269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.
    Rong SL; Leonard SN
    Ann Pharmacother; 2010 May; 44(5):844-50. PubMed ID: 20332341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
    Fritsche TR; Rhomberg PR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
    Franchi D; Climo MW; Wong AH; Edmond MB; Wenzel RP
    Clin Infect Dis; 1999 Dec; 29(6):1566-8. PubMed ID: 10585815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Leonard SN; Rossi KL; Newton KL; Rybak MJ
    J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vancomycin resistance in Staphylococcus aureus.
    Appelbaum PC; Bozdogan B
    Clin Lab Med; 2004 Jun; 24(2):381-402. PubMed ID: 15177846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.